Injectable Semaglutide and Reductions in HbA1c and Weight in the Real World in People Switched from Alternative Glucagon-like Peptide-1 Receptor Agonists

Overview

Journal Diabetes Obes Metab

Specialty Endocrinology

Date 2022 Mar 24

PMID 35322528

Authors

Thomas S J Crabtree

Karen Adamson

Hazel Reid

Dennis Barnes

Siva Sivappriyan

Alex Bickerton

Ian W Gallen

Benjamin C T Field

Iskandar Idris

Robert E J Ryder

Affiliations

Soon will be listed here.

Abstract

The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure. The analysis, in this research letter, shows that decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP-1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide, potentially suggesting differing potencies between GLP-1RAs. Dedicated studies with head-to-head comparisons are needed to confirm these findings.

Citing Articles

Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice.

Pantanetti P, Cangelosi G, Alberti S, Di Marco S, Michetti G, Cerasoli G Front Endocrinol (Lausanne). 2024; 15:1394506.

PMID: 39015186 PMC: 11250060. DOI: 10.3389/fendo.2024.1394506.

Real-world HbA changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes.

Frazer M, Swift C, Sargent A, Leszko M, Buysman E, Gronroos N J Diabetes Metab Disord. 2024; 23(1):727-737.

PMID: 38932879 PMC: 11196477. DOI: 10.1007/s40200-023-01341-y.

Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study.

McKenzie A, Athinarayanan S Diabetes Ther. 2024; 15(4):843-853.

PMID: 38421559 PMC: 10951146. DOI: 10.1007/s13300-024-01547-0.

Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study.

Omachi T, Ohara M, Fujikawa T, Kohata Y, Sugita H, Irie S Diabetes Ther. 2023; 15(1):111-126.

PMID: 37880502 PMC: 10786762. DOI: 10.1007/s13300-023-01493-3.

Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.

Crabtree T, Adamson K, Reid H, Barnes D, Sivappriyan S, Bickerton A Diabetes Obes Metab. 2022; 24(7):1398-1401.

PMID: 35322528 PMC: 9322019. DOI: 10.1111/dom.14701.

References

Williams D, Ruslan A, Khan R, Vijayasingam D, Iqbal F, Shaikh A . Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study. Diabetes Ther. 2021; 12(3):801-811. PMC: 7872110. DOI: 10.1007/s13300-021-01015-z. View

Crabtree T, Adamson K, Reid H, Barnes D, Sivappriyan S, Bickerton A . Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2022; 24(7):1398-1401. PMC: 9322019. DOI: 10.1111/dom.14701. View

Lingvay I, Kirk A, Lophaven S, Wolden M, Shubrook J . Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study. Diabetes Ther. 2021; 12(3):879-896. PMC: 7947062. DOI: 10.1007/s13300-021-01010-4. View

Visaria J, Uzoigwe C, Swift C, Dang-Tan T, Paprocki Y, Willey V . Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population. Clin Ther. 2021; 43(5):808-821. DOI: 10.1016/j.clinthera.2021.03.003. View

Frias J, Bonora E, Nevarez Ruiz L, Li Y, Yu Z, Milicevic Z . Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021; 44(3):765-773. PMC: 7896253. DOI: 10.2337/dc20-1473. View

Sorli C, Harashima S, Tsoukas G, Unger J, Karsbol J, Hansen T . Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017; 5(4):251-260. DOI: 10.1016/S2213-8587(17)30013-X. View

Witkowski M, Wilkinson L, Webb N, Weids A, Glah D, Vrazic H . A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs. Diabetes Ther. 2018; 9(3):1149-1167. PMC: 5984927. DOI: 10.1007/s13300-018-0424-2. View

Rubino D, Greenway F, Khalid U, ONeil P, Rosenstock J, Sorrig R . Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022; 327(2):138-150. PMC: 8753508. DOI: 10.1001/jama.2021.23619. View

Hepprich M, Zillig D, Florian-Reynoso M, Donath M, Rudofsky G . Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. Diabetes Ther. 2021; 12(3):943-954. PMC: 7947039. DOI: 10.1007/s13300-021-01016-y. View

10.

Hansen K, Svendstrup M, Lund A, Knop F, Vilsboll T, Vestergaard H . Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic. Diabet Med. 2021; 38(10):e14655. DOI: 10.1111/dme.14655. View

11.

Ahmann A, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I . Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2017; 41(2):258-266. DOI: 10.2337/dc17-0417. View

12.

Pratley R, Aroda V, Lingvay I, Ludemann J, Andreassen C, Navarria A . Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018; 6(4):275-286. DOI: 10.1016/S2213-8587(18)30024-X. View